Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $15

Needham analyst Ami Fadia maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and lowers the price target from $16 to $15.

byBenzinga Newsdesk

January 11, 2022

1 minute read

Needham analyst Ami Fadia maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and lowers the price target from $16 to $15.

Wells Fargo Maintains Equal-Weight on NuStar Energy, Lowers Price Target to $17

By Benzinga Newsdesk

Today, 3:19 AM

Wells Fargo analyst Michael Blum maintains NuStar Energy (NYSE:NS) with a Equal-Weight and lowers the price target from $18 to $17.

$100 Invested In Charter Communications 10 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 3:19 AM

Charter Communications (NASDAQ:CHTR) has outperformed the market over the past 10 years by 8.42% on an annualized basis producing an average annual return of 19.33%. Currently, Charter Communications has a market capitalization of $79.44 billion.

CHTR

FDA
News

CNBC’s Meg Meg Tirrell Tweeted: CDC director overrules advisory committee, recommending #covid19 booster dose for all categorizes FDA authorized

By Charles Gross

Today, 3:19 AM

https://twitter.com/megtirrell/status/1441331243887456257

BNTX

Target Q2 Result Tops Estimates, Margin Shrinks; Plans $15B Stock Buyback

By Shivani Kumaresan

Today, 3:19 AM

Target Corp (NYSE:TGT) reported second-quarter FY21 revenue growth of 9.5% year-on-year, to $25.16 billion, beating the analyst consensus of $25.08 billion.…

TGT

Needham Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $15

Related Posts

Wells Fargo Maintains Equal-Weight on NuStar Energy, Lowers Price Target to $17

$100 Invested In Charter Communications 10 Years Ago Would Be Worth This Much Today

CNBC’s Meg Meg Tirrell Tweeted: CDC director overrules advisory committee, recommending #covid19 booster dose for all categorizes FDA authorized

Target Q2 Result Tops Estimates, Margin Shrinks; Plans $15B Stock Buyback